Head and neck cancer (squamous cell carcinoma) - cetuximab (TA172)
Fast, easy summary view of NICE guidance on 'head and neck cancer'
Cetuximab for the treatment of metastatic and/or recurrent squamous cell carcinoma of the head and neck
Cetuximab in combination with platinum-based chemotherapy is not recommended for people with recurrent and/or metastatic squamous cell cancer of the head and neck.
Healthcare professionals should not stop prescribing cetuximab in combination with platinum-based chemotherapy for people who were already taking it when the guidance was issued. These people should be able to carry on taking cetuximab until they and their healthcare professionals decide that it is the right time to stop treatment.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: head and neck cancer
This page was last updated: 02 April 2014
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA172 Cetuximab fel triniaeth ar gyfer canser celloedd cennog y pen a'r gwddf sy'n dychwelyd a/neu sy'n fetastatig: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.